GermanyGermany

Autoimmune treatment

13.05.2010

Martinsried – SuppreMol GmbH has enrolled the first patient in a Phase Ib/IIa clinical trial with SM101, a treatment for Idiopathic Thrombocytopenic Purpura (ITP). Up to 36 patients will receive 4 weekly doses of the recombinant, soluble, non-glycosylated version of the Fcg receptor IIb, or matching placebo intravenously. Subsequently, SuppreMol plans to enroll an additional 15 patients to expand the study to a Phase IIa parallel-group clinical trial. Primary endpoint is the incidence of adverse events. The main efficacy endpoint is the proportion of subjects with a substantial platelet response. Secondary endpoints comprise number of bleeding events, time to reach platelet response, duration of platelet response, proportion of subjects with rescue medication, and dose reduction of concomitant ITP medication.

Germany, FranceGermany

21.12.2011

Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...

GermanyGermany

20.12.2011

Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...

GermanyGermany

16.12.2011

Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...

GermanyGermany

15.12.2011

Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...

GermanyGermany

15.12.2011

While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...

GermanyGermany

08.12.2011

Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...

GermanyGermany

03.11.2011

Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....

GermanyGermany

02.11.2011

Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/1/article/autoimmune-treatment.html

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week

Products

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • NEOVACS (F)1.25 EUR15.74%
  • SCANCELL HOLDINGS (UK)38.25 GBP14.18%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-53.97%
  • ANTISOMA (UK)1.00 GBP-35.48%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • HYBRIGENICS (F)1.86 EUR44.2%
  • GALAPAGOS (B)51.13 EUR36.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-56.7%
  • CYTOS (CH)0.61 CHF-39.6%
  • ANTISOMA (UK)1.00 GBP-35.5%

TOP

  • CELLECTIS (F)38.35 EUR517.6%
  • WILEX (D)4.30 EUR465.8%
  • ADOCIA (F)69.01 EUR432.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-81.8%
  • THROMBOGENICS (B)5.32 EUR-70.2%
  • ACTIVE BIOTECH (S)10.60 SEK-68.8%

No liability assumed, Date: 01.06.2015

Current issue

All issues